期刊文献+

糖皮质激素、硫唑嘌呤联合乙酰半胱氨酸治疗特发性间质性肺炎的效果 被引量:34

下载PDF
导出
摘要 目的研究糖皮质激素、硫唑嘌呤、乙酰半胱氨酸三药联合治疗特发性间质性肺炎的临床效果。方法遴选住院治疗的特发性间质性肺炎患者46例,依据随机原则,分为观察组及对照组,每组23例。对照组口服强的松、硫唑嘌呤,观察组口服强的松、硫唑嘌呤、乙酰半胱氨酸。比较两组临床效果、肺功能及血气分析变化的不同。结果治疗前后,两组患者在临床效果、肺功能和血气分析上差异均有统计学意义(P<0.05)。结论糖皮质激素、硫唑嘌呤、乙酰半胱氨酸三药联合可以有效改善特发性间质性肺炎患者的呼吸困难等症状,并可有效地改善患者的肺功能、血气分析指标,临床应用推广价值大。
作者 徐虹 卢慧宇
出处 《广东医学》 CAS 北大核心 2016年第16期2492-2493,共2页 Guangdong Medical Journal
  • 相关文献

参考文献6

二级参考文献14

  • 1DOMICIANO D S, BONFA E, BORGES C T, et al. A long- term prospective randomized controlled study of non - specific in- terstitial pneumonia (NSIP) treatment in scleroderma [ J] Clin Rheumatol, 2011, 30(2): 223-229.
  • 2TASHKIN D P, ELASHOFF R, CLEMENTS P J, et al. Effects of 1 -year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease [ J]. Am J Respir Crit Care Med, 2007, 176(10): 1026-1034.
  • 3American Thoracic Society/European Respiratory Society Interna- tional Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Tho- racic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 [ J]. Am J Respir Crit Care Med, 2002, 165(2) : 277 -304.
  • 4HELBICH T H, HEINZ PEER G, EICHLER I, et al. Cystic fi- brosis: CT assessment of lung involvement in children and adults [J]. Radiology, 1999, 213(2) : 537 -544.
  • 5AUSTIN J H, MULLER N L, FRIEDMAN P J, et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleisehner Society [ J ]. Radiology, 1996, 200 (2) : 327 -331.
  • 6CASTELINO F V, VARGA J. Interstitial lung disease in connec- tive tissue diseases : evolving concepts of pathogenesis and manage- ment[J]. Arthritis Res Ther, 2010, 12(4) : 213.
  • 7BUSSONE G, MOUTHON L. Interstitial lung disease in systemic sclerosis[J]. Autoimmun Rev, 2011, 10(5) : 248 -255.
  • 8DE LAURETIS A, VEERARAGHAVAN S, RENZONI E. Review series: Aspects of interstitial lung disease: connective tissue dis- ease -associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? [ J]. Chron Respir Dis, 2011, 8(1) : 53 -82.
  • 9TZELEPIS G E, PLASTIRAS S C, KARADIMITRAKIS S P, et al. Determinants of pulmonary function improvement in patients with scteroderma and interstitial lung disease[ J]. Clin Exp Rheu- matol, 2007, 25 (5) : 734 - 739.
  • 10YAMASAKI Y, YAMADA H, YAMASAKI M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis [ J ]. Rheumatology (Oxford), 2007, 46(1) : 124 -130.

共引文献656

同被引文献218

引证文献34

二级引证文献183

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部